TN-201 Received Fast Track Designation from the FDA Dosing Complete in Phase 1 Clinical Trial of TN-301; Data Expected in Second Half 2023 Renowned Researchers Drs. Christine Seidman and Alex Marson... | May 10, 2023
Appointment brings extensive operational expertise in supply chain and novel commercial-scale manufacturing systems SOUTH SAN FRANCISCO, Calif., March ...
29.03.2022 - Appointment brings extensive operational expertise in supply chain and novel commercial-scale manufacturing systems SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) - Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical ... Seite 1
Adverum Announces Board Slate for 2021 Annual Meeting and Reiterates Commitment to Stockholder Value Creation
Equity Performance: from Sonic Fund letter to Adverum
Equity Performance: from Sonic Fund letter to Adverum
Image 1: from Sonic Fund letter to Adverum
Image 1: from Sonic Fund letter to Adverum
Image 2: from Sonic Fund letter to Adverum
Image 2: from Sonic Fund letter to Adverum
Image 3: from Sonic Fund letter to Adverum
Image 3: from Sonic Fund letter to Adverum
Image 4: from Sonic Fund letter to Adverum
Image 4: from Sonic Fund letter to Adverum
Image 5: from Sonic Fund letter to Adverum
Image 5: from Sonic Fund letter to Adverum
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced plans...
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Adverum Biotechnologies Announces New GMP Gene Therapy Manufacturing Facility
Adverum Biotechnologies, Inc.January 7, 2021 GMT
-- 174,000-square-foot commercial GMP facility in Durham, NC for the manufacturing of ADVM-022, an intravitreal gene therapy in development for wet AMD and DME --
-- Multiple production suites with total capacity of 4000L, with further expansion opportunities --
-- Adverum to invest over $80M to be production-ready by end of 2023 and create more than 200 life sciences jobs; Company to receive state and local incentives of up to $9M --
by Jim Shamp, NCBiotech writer — January 7, 2021 .
RESEARCH TRIANGLE PARK – California gene therapy innovator Adverum Biotechnologies announced plans today to invest $83 million to establish a manufacturing site in Durham that will employ 202 people at an average salary of $93,762 when fully operational.
It’s the latest in a string of cell- and gene-therapy companies drawn to the Triangle for its trained workforce, academic prowess and attractive business, social and meteorological climate.
The publicly held company, (Nasdaq: ADVM), is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum’s lead product candidate, ADVM-022, is a one-time injection into the eye to treat conditions such as wet age-related macular degeneration and diabetic macular edema.